JP2010501594A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501594A5
JP2010501594A5 JP2009525853A JP2009525853A JP2010501594A5 JP 2010501594 A5 JP2010501594 A5 JP 2010501594A5 JP 2009525853 A JP2009525853 A JP 2009525853A JP 2009525853 A JP2009525853 A JP 2009525853A JP 2010501594 A5 JP2010501594 A5 JP 2010501594A5
Authority
JP
Japan
Prior art keywords
variable region
glycoprotein
hcv
modified
linker sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009525853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501594A (ja
JP2010501594A6 (ja
JP5674310B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2007/001221 external-priority patent/WO2008022401A1/en
Publication of JP2010501594A publication Critical patent/JP2010501594A/ja
Publication of JP2010501594A6 publication Critical patent/JP2010501594A6/ja
Publication of JP2010501594A5 publication Critical patent/JP2010501594A5/ja
Application granted granted Critical
Publication of JP5674310B2 publication Critical patent/JP5674310B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009525853A 2006-08-25 2007-08-24 組換えｈｃｖ ｅ２糖タンパク質 Expired - Fee Related JP5674310B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2006904635A AU2006904635A0 (en) 2006-08-25 Recombinant E2 Envelope Glycoprotein for Improved Treatment of HCV virus
AU2006904635 2006-08-25
AU2006906090A AU2006906090A0 (en) 2006-11-01 Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
AU2006906090 2006-11-01
AU2006906282A AU2006906282A0 (en) 2006-11-10 Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
AU2006906282 2006-11-10
PCT/AU2007/001221 WO2008022401A1 (en) 2006-08-25 2007-08-24 Recombinant hcv e2 glycoprotein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014185095A Division JP5999524B2 (ja) 2006-08-25 2014-09-11 組換えｈｃｖｅ２糖タンパク質

Publications (4)

Publication Number Publication Date
JP2010501594A JP2010501594A (ja) 2010-01-21
JP2010501594A6 JP2010501594A6 (ja) 2010-04-15
JP2010501594A5 true JP2010501594A5 (enExample) 2010-10-07
JP5674310B2 JP5674310B2 (ja) 2015-02-25

Family

ID=39106399

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009525853A Expired - Fee Related JP5674310B2 (ja) 2006-08-25 2007-08-24 組換えｈｃｖ ｅ２糖タンパク質
JP2014185095A Expired - Fee Related JP5999524B2 (ja) 2006-08-25 2014-09-11 組換えｈｃｖｅ２糖タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014185095A Expired - Fee Related JP5999524B2 (ja) 2006-08-25 2014-09-11 組換えｈｃｖｅ２糖タンパク質

Country Status (8)

Country Link
US (2) US8535686B2 (enExample)
EP (1) EP2061805B1 (enExample)
JP (2) JP5674310B2 (enExample)
KR (1) KR101500017B1 (enExample)
CN (1) CN101563362B (enExample)
AU (1) AU2007288129B2 (enExample)
CA (1) CA2661814A1 (enExample)
WO (1) WO2008022401A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061805B1 (en) * 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
WO2009131681A2 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
EP2297187A1 (en) * 2008-06-03 2011-03-23 Okairos AG A vaccine for the prevention and therapy of hcv infections
CA2658714A1 (en) * 2009-03-17 2010-09-17 Thomas Krey Hcv-derived polypeptides and uses thereof
CN102199613A (zh) * 2010-03-25 2011-09-28 国立大学法人东京大学 感染性丙型肝炎病毒高生产hcv突变体及其应用
EP2600894B1 (en) 2010-08-04 2017-02-01 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Modified hepatitis c virus proteins
AU2011334543B2 (en) * 2010-11-26 2015-05-21 The Macfarlane Burnet Institute For Medical Research And Public Health Compositions and methods
WO2013033319A2 (en) * 2011-08-30 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University A cluster of neutralizing antibodies to hepatitis c virus
CN103102394B (zh) * 2013-02-27 2014-06-25 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi49及其应用
CN110049993A (zh) * 2016-09-29 2019-07-23 麦克法兰布奈特医疗研究与公共健康研究所有限公司 组装的糖蛋白
WO2021021603A2 (en) * 2019-07-26 2021-02-04 The Scripps Research Institute Engineered hcv e2 immunogens and related vaccine compositions
JP2023526045A (ja) * 2020-05-11 2023-06-20 マクファーレン バーネット インスティテュート フォー メディカル リサーチ アンド パブリック ヘルス リミテッド 可変ドメイン欠失ｅ２ポリペプチドを含むｃ型肝炎核酸ワクチン
CN112730851B (zh) * 2021-03-31 2021-06-22 南京立顶医疗科技有限公司 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129337B1 (en) * 1994-10-21 2006-10-31 Innogenetics N.V. Sequences of hepatitis C virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
WO2000026418A1 (en) 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
WO2001021807A1 (en) * 1999-09-23 2001-03-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
EP1326625A4 (en) * 2000-09-13 2005-05-04 Hawaii Biotech Inc IMMUNOGENIC COMPOSITION OF HEPATITIS C AND METHODS FOR ITS USE
PL366621A1 (en) * 2001-04-24 2005-02-07 Innogenetics N.V. Core-glycosylated hcv envelope proteins
IL145440A0 (en) 2001-09-13 2002-06-30 Xtl Biopharmaceuticals Ltd Synthetic hcv envelope proteins and their use for vaccination
CA2552949C (en) * 2004-01-07 2012-10-02 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
EP2061805B1 (en) * 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein

Similar Documents

Publication Publication Date Title
JP2010501594A5 (enExample)
US6951646B1 (en) Anti hepatitis C virus antibody and uses thereof
Keck et al. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice
ES2926511T3 (es) Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos
JP2012504602A5 (enExample)
Lazo et al. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus
PT1835937E (pt) Composições e métodos para tratar infeção viral
EA201170353A1 (ru) Антитела против гепатита с и их применение
JP2012531219A5 (enExample)
JP2018512124A5 (enExample)
JP2005528914A5 (enExample)
Arribillaga et al. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus
JP2018537117A5 (enExample)
JP2008532559A5 (enExample)
JP2006504645A5 (enExample)
JP5897024B2 (ja) 組成物および方法
JP2006523185A5 (enExample)
US20080248042A1 (en) Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
CN105254756B (zh) 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
El-Awady et al. Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats
CN109627297A (zh) 来自寨卡病毒e蛋白的中和表位及其应用
TWI432211B (zh) 與登革病毒相關之胜肽及抗體以及其用途
EP2705369B1 (fr) Procédé pour la détection d'une infection par le virus de la dengue
Takao et al. Antibody reactive to a hepatitis C virus (HCV)‐derived peptide capable of inducing HLA‐A2 restricted cytotoxic T lymphocytes is detectable in a majority of HCV‐infected individuals without HLA‐A2 restriction
CN107286237B (zh) 一种抗丙型肝炎病毒抗体的获取以及应用